APC is altered in 10.56% of anaplastic oligodendroglioma patients [2].

APC is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains APC status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

CDK6 is altered in 0.62% of anaplastic oligodendroglioma patients [2].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

CTDNEP1 is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains CTDNEP1 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

CTNNB1 is altered in 1.67% of anaplastic oligodendroglioma patients [2].

CTNNB1 is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains CTNNB1 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

DDX3X is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains DDX3X status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

EGFR is altered in 3.89% of anaplastic oligodendroglioma patients [2].

EGFR is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains EGFR status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

FGF19 is altered in 1.74% of anaplastic oligodendroglioma patients [2].

FGF19 is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains FGF19 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF9 is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains FGF9 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR1 is altered in 5.56% of anaplastic oligodendroglioma patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR2 is altered in 3.89% of anaplastic oligodendroglioma patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR3 is altered in 4.44% of anaplastic oligodendroglioma patients [2].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR4 is altered in 1.21% of anaplastic oligodendroglioma patients [2].

FGFR4 is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains FGFR4 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

GLI2 is altered in 5.56% of anaplastic oligodendroglioma patients [2].

GLI2 is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains GLI2 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

H3F3A is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains H3F3A status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

IDH1 is altered in 82.22% of anaplastic oligodendroglioma patients [2].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

IDH2 is altered in 13.33% of anaplastic oligodendroglioma patients [2].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

KDM6A is altered in 4.97% of anaplastic oligodendroglioma patients [2].

KDM6A is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains KDM6A status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2C is altered in 10.42% of anaplastic oligodendroglioma patients [2].

KMT2C is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains KMT2C status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

KMT2D is altered in 14.29% of anaplastic oligodendroglioma patients [2].

KMT2D is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains KMT2D status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

LRP1B is altered in 5.48% of anaplastic oligodendroglioma patients [2].

LRP1B is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains LRP1B status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM4 is altered in 1.24% of anaplastic oligodendroglioma patients [2].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYC is altered in 1.86% of anaplastic oligodendroglioma patients [2].

MYC is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains MYC status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYCL is altered in 1.86% of anaplastic oligodendroglioma patients [2].

MYCL is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains MYCL status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

MYCN is altered in 1.24% of anaplastic oligodendroglioma patients [2].

MYCN is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains MYCN status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

OTX2 is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains OTX2 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PPM1D is altered in 4.27% of anaplastic oligodendroglioma patients [2].

PPM1D is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains PPM1D status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PTCH1 is altered in 4.97% of anaplastic oligodendroglioma patients [2].

PTCH1 is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains PTCH1 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PTEN is altered in 2.22% of anaplastic oligodendroglioma patients [2].

PTEN is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

PVT1 is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains PVT1 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

RELA is altered in 1.41% of anaplastic oligodendroglioma patients [2].

RELA is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains RELA status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SHH is altered in 1.72% of anaplastic oligodendroglioma patients [2].

SHH is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains SHH status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SMARCA4 is altered in 13.66% of anaplastic oligodendroglioma patients [2].

SMARCA4 is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains SMARCA4 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SMO is altered in 2.78% of anaplastic oligodendroglioma patients [2].

SMO is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains SMO status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SNCAIP is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains SNCAIP status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

SUFU is altered in 3.73% of anaplastic oligodendroglioma patients [2].

SUFU is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains SUFU status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

TERT is altered in 4.0% of anaplastic oligodendroglioma patients [2].

TERT is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains TERT status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

TP53 is altered in 12.78% of anaplastic oligodendroglioma patients [2].

TP53 is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

YAP1 is altered in 1.99% of anaplastic oligodendroglioma patients [2].

YAP1 is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains YAP1 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].

ZMYM3 is altered in 3.23% of anaplastic oligodendroglioma patients [2].

ZMYM3 is an inclusion eligibility criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains ZMYM3 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [3].